A REVIEW ON INNOVATION IN IMMUNODULATORY THERAPIES FOR NEUROLOGICAL DISORDER FOR ALHEIMER'S DISEASE AND MYASTHENIA GRAVIS

Neuroimmune interactions play a key role in disorders like Alzheimer’s disease (AD) and Myasthenia Gravis (MG). Recent immunomodulatory therapies offer targeted approaches to reduce neuroinflammation and slow disease progression. In AD, monoclonal antibodies target beta-amyloid and tau, while microglial modulators, Treg therapies, complement inhibitors, and gut-brain axis interventions support neuroprotection. In MG, therapies include B-cell depletion, complement inhibition, and cytokine targeting. Advanced options like Treg infusions, CAR-T cells, stem cells, and small molecule modulators (e.g., S1P and BTK inhibitors) show promise. Innovations in drug delivery, biomarker-based treatments, and AI-driven drug development are advancing personalized neurology, offering more effective and long-lasting outcomes.